Information Provided By:
Fly News Breaks for October 21, 2015
CPHD
Oct 21, 2015 | 06:32 EDT
Canaccord downgraded Cepheid to Hold and lowered its price target to $34 from $42 on shares following Q3 results. Analyst Mark Massaro is concerned Cepheid will not meet 2017 financial targets given the "major disruption" to the sales force and concerns about the decelerating commercial clinical reagent growth the flattening growth of its lead assay, MRSA, as well as its recent overrun in spend manufacturing virology assays.
News For CPHD From the Last 2 Days
There are no results for your query CPHD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.